{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T16:00:32Z","timestamp":1717689632259},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.bbrc.2011.10.038","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T18:58:49Z","timestamp":1319050729000},"page":"274-278","source":"Crossref","is-referenced-by-count":17,"title":["Proteasome inhibitors improve the function of mutant lysosomal \u03b1-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation"],"prefix":"10.1016","volume":"415","author":[{"given":"Yohta","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2011.10.038_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2011.10.038_b0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.bbrc.2011.10.038_b0015","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2011.10.038_b0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2011.10.038_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbrc.2011.10.038_b0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbrc.2011.10.038_b0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic prote","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.bbrc.2011.10.038_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","article-title":"A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity","volume":"389","author":"Fan","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbrc.2011.10.038_b0045","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbrc.2011.10.038_b0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbrc.2011.10.038_b0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2011.10.038_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2011.09.005","article-title":"Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546 G>T mutation","author":"Shimada","year":"2011","journal-title":"Mol. Genet. Metab"},{"key":"10.1016\/j.bbrc.2011.10.038_b0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gt.2009.160","article-title":"Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction","volume":"17","author":"Kyosen","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbrc.2011.10.038_b0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"The proteasome: a novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2011.10.038_b0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/humu.10286","article-title":"Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II","volume":"23","author":"Hermans","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbrc.2011.10.038_b0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2011.10.038_b0085","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher\u2019s disease","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbrc.2011.10.038_b0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2011.10.038_b0095","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2011.10.038_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2011.10.038_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","article-title":"Proteasome inhibitors: valuable new tools for cell biologists","volume":"8","author":"Lee","year":"1998","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbrc.2011.10.038_b0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","article-title":"Proteasome inhibition: a new anti-inflammatory strategy","volume":"81","author":"Elliott","year":"2003","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bbrc.2011.10.038_b0115","first-page":"828","article-title":"Bortezomib (millennium pharmaceuticals)","volume":"5","author":"Dou","year":"2002","journal-title":"IDrugs"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X11018353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X11018353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T09:54:06Z","timestamp":1543485246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X11018353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0006291X11018353"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2011.10.038","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}